مقالات پذیرفته شده در سومین کنگره بین المللی زیست پزشکی
A review of personalized Medicine therapeutic approaches to treating lung cancer
A review of personalized Medicine therapeutic approaches to treating lung cancer
Mahdi Shirazi,1,*
1. Islamic Azad university , Varamin-Pishva branch
Introduction: Lung cancer is known as one of the deadliest and most costly types of cancer in the world. Almost all lung cancers are associated with smoking. There is only one common type of lung cancer that is not related to smoking and it is the lung adenocarcinoma. Lung adenocarcinoma is a secondary cause of lung inflammation and chronic pulmonary infections. The results of epidemiological studies indicate that the prevalence rate of this type of cancer in Iran will increase significantly between 2014 and 2030. Current treatments are not a definitive answer to this type of cancer, and many patients with "small cell" will be malignant if they do not receive treatment and live for about 4 months. But the truth is that even after treatment, many of these patients are at risk of recurrence and more than 50% of these patients die after 12 months. Given the fatalities of this type of cancer and the costs of medication and old treatments, alternative therapies with a "personalized medicine" and "cell therapy" approach can be promising in treating this type of cancer. Currently, vaccine design as a part of immunotherapy can be useful in the treatment of lung cancer and NSCLC tumors. These vaccines are designed based on the characteristics of the targeted antigen, and have shown good performance results in the research. In recent years, treatment with "stem cells" has also grown as an integral part of cell therapy. According to the research, there is widespread evidence that stem cell therapy is more resistant to current drug and chemotherapy treatments, and the risk of recurrence is also lower. In personalized medicine, therapeutic approaches are approved using tyrosine kinase (TKI) and anaplastic lymphoma kinase (ALK) and monoclonal antibodies. In short, the use of this therapeutic approach requires the accurate recognition of the gene profile and the determination of the target gene in the affected person.
Methods: Surveying different articles related to the subject in recent years with using several internet search engines like google chrome, PubMed, and Scopus.
Results: For the treatment of lung cancer, cell-based therapy with the potential for repairing cancerous tissue is superior to previous therapies, as well as chemotherapy and drug therapy. With less than 5 years of survival in lung cancer and extensive treatment costs, preventive treatments such as vaccine design and newer therapies based on "personalized medicine" have better results and, in addition to the serious treatment of the disease, has the risk of recurrence Also reduces.
Conclusion: In short, with recent studies, it can be concluded that stem cell transplantation, vaccine design based on target antigen, and the use of personal medicine in the treatment of lung cancer are more beneficial and the cost of drug and chemotherapy treatments It will also not result in. And more importantly, the number of deaths caused by this type of cancer also decreases significantly.